Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life and Intracellular Targeting Strategies with a Strategy to Boost CD4+ T Cell

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2007 Oct 18

PMID 17939748

Citations 11

Authors

Daejin Kim

Talia Hoory

T-C Wu

Chien-Fu Hung

Affiliations

Soon will be listed here.

Abstract

Intradermal administration of DNA vaccines, using a gene gun, represents an effective means of delivering DNA directly into professional antigen-presenting cells (APCs) in the skin and thus allows the application of strategies to modify the properties of APCs to enhance DNA vaccine potency. In the current study, we hypothesized that the potency of human papillomavirus (HPV) type 16 E7 DNA vaccines employing intracellular targeting strategies combined with a strategy to prolong the life of dendritic cells (DCs) could be further enhanced by the addition of a DNA vaccine capable of generating high numbers of pan-HLA-DR reactive epitope (PADRE)-specific CD4(+) T cells. We observed that the addition of PADRE DNA to E7 DNA vaccines employing intracellular targeting strategies with a strategy to prolong the life of DCs led to significant enhancement of E7-specific CD8(+) effector and memory T cells as well as significantly improved therapeutic effects against established E7-expressing tumors in tumor-challenged mice. Our data suggest that the potency of a DNA vaccine combining an intracellular targeting strategy as well as a strategy to prolong the life of DCs can be further enhanced by addition of DNA that is capable of generating high numbers of PADRE-specific CD4(+) T cells.

Citing Articles

Analysis of the effect of promoter type and skin pretreatment on antigen expression and antibody response after gene gun-based immunization.

Vij R, Lin Z, Schneider K, Seshasayee D, Koerber J PLoS One. 2018; 13(6):e0197962.

PMID: 29856790 PMC: 5983433. DOI: 10.1371/journal.pone.0197962.

Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX.

Liu J, Feng K, Zhao L, Luo H, Zhu Y Exp Ther Med. 2017; 13(6):3275-3280.

PMID: 28587400 PMC: 5450512. DOI: 10.3892/etm.2017.4385.

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.

Yang B, Yang A, Peng S, Pang X, Roden R, Wu T Cell Biosci. 2015; 5:35.

PMID: 26113972 PMC: 4480891. DOI: 10.1186/s13578-015-0025-y.

Basic and translational applications of engineered MHC class I proteins.

Hansen T, Connolly J, Gould K, Fremont D Trends Immunol. 2010; 31(10):363-9.

PMID: 20832361 PMC: 2949479. DOI: 10.1016/j.it.2010.07.003.

Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine.

Huang C, Chang C, Lin C, Wang S, Wu M, Li E Cancer Immunol Immunother. 2010; 59(8):1259-72.

PMID: 20390417 PMC: 11030179. DOI: 10.1007/s00262-010-0852-y.

References

Porgador A, Irvine K, Iwasaki A, Barber B, Restifo N, Germain R . Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med. 1998; 188(6):1075-82. PMC: 2212529. DOI: 10.1084/jem.188.6.1075. View

Mitchison N, OMalley C . Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur J Immunol. 1987; 17(11):1579-83. DOI: 10.1002/eji.1830171109. View

Hung C, Yang M, Wu T . Modifying professional antigen-presenting cells to enhance DNA vaccine potency. Methods Mol Med. 2006; 127:199-220. DOI: 10.1385/1-59745-168-1:199. View

Castellino F, Germain R . Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006; 24:519-40. DOI: 10.1146/annurev.immunol.23.021704.115825. View

Bevan M . Helping the CD8(+) T-cell response. Nat Rev Immunol. 2004; 4(8):595-602. DOI: 10.1038/nri1413. View

Condon C, Watkins S, Celluzzi C, Thompson K, Falo Jr L . DNA-based immunization by in vivo transfection of dendritic cells. Nat Med. 1996; 2(10):1122-8. DOI: 10.1038/nm1096-1122. View

Cheng W, Hung C, Chai C, Hsu K, He L, Ling M . Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001; 108(5):669-78. PMC: 209378. DOI: 10.1172/JCI12346. View

Kim T, Hung C, Ling M, Juang J, He L, Hardwick J . Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest. 2003; 112(1):109-17. PMC: 162284. DOI: 10.1172/JCI17293. View

Cheng W, Hung C, Chai C, Hsu K, He L, Rice C . Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol. 2001; 166(10):6218-26. DOI: 10.4049/jimmunol.166.10.6218. View

10.

Bennett S, Carbone F, Karamalis F, Miller J, Heath W . Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med. 1997; 186(1):65-70. PMC: 2198964. DOI: 10.1084/jem.186.1.65. View

11.

Hung C, Tsai Y, He L, Wu T . DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther. 2007; 15(6):1211-9. PMC: 3171992. DOI: 10.1038/sj.mt.6300121. View

12.

Moniz M, Ling M, Hung C, Wu T . HPV DNA vaccines. Front Biosci. 2002; 8:d55-68. DOI: 10.2741/936. View

13.

Xiang J, Huang H, Liu Y . A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol. 2005; 174(12):7497-505. DOI: 10.4049/jimmunol.174.12.7497. View

14.

Bousso P, Robey E . Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol. 2003; 4(6):579-85. DOI: 10.1038/ni928. View

15.

Tsen S, Paik A, Hung C, Wu T . Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007; 6(2):227-39. PMC: 3190226. DOI: 10.1586/14760584.6.2.227. View

16.

Hung C, Cheng W, Hsu K, Chai C, He L, Ling M . Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 2001; 61(9):3698-703. View

17.

Castellino F, Huang A, Altan-Bonnet G, Stoll S, Scheinecker C, Germain R . Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006; 440(7086):890-5. DOI: 10.1038/nature04651. View

18.

Ji H, Wang T, Chen C, Pai S, Hung C, Lin K . Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther. 1999; 10(17):2727-40. DOI: 10.1089/10430349950016474. View

19.

Kim T, Hung C, Boyd D, Juang J, He L, Kim J . Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol. 2003; 171(6):2970-6. DOI: 10.4049/jimmunol.171.6.2970. View

20.

Chen C, Wang T, Hung C, Yang Y, Young R, Pardoll D . Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 2000; 60(4):1035-42. View